MiNK Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MiNK Therapeutics, Inc. | ||
| Date: March 21, 2024 | By: | /s/ Jennifer S. Buell, Ph.D. |
|---|---|---|
| Jennifer S. Buell, Ph.D. | ||
| President, Chief Executive Officer and Director | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Jennifer S. Buell, Ph.D. | President, Chief Executive Officer and Director | March 21, 2024 |
| Jennifer S. Buell, Ph.D. | (Principal Executive Officer) | |
| /s/ Christine M. Klaskin | Treasurer (Principal Financial Officer and Principal | March 21, 2024 |
| Christine M. Klaskin | Accounting Officer) | |
| /s/ Garo H. Armen, Ph.D. | Chairman of the Board of Directors | March 21, 2024 |
| Garo H. Armen, Ph.D. | ||
| /s/ Peter Behner | Director | March 21, 2024 |
| Peter Behner | ||
| /s/ Brian Corvese | Director | March 21, 2024 |
| Brian Corvese | ||
| /s/ Barbara Ryan | Director | March 21, 2024 |
| Barbara Ryan | ||
| /s/ Ulf Wiinberg | Director | March 21, 2024 |
| Ulf Wiinberg | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.